According to the American Diabetes Association (ADA)/ European Association for the Study of Diabetes (EASD) guideline, a patient-centered approach to type 2 diabetes (T2D) management should be adopted with the goal of not only preventing complications but also optimizing patients’ quality of life.1 To achieve these goals, factors that affect health-related quality of life (HRQoL) such as social determinants of health, psychosocial well-being, and health behaviors are key considerations in glycemic management strategies for patients with T2D.1 At the EASD Annual Meeting 2023, Professor Chan, Chung-Ngor Juliana from the Department of Medicine and Therapeutics, The Chinese University of Hong Kong presented the results of a cross-sectional analysis of HRQoL in patients with T2D treated with oral glucose-lowering drugs (OGLDs) who were enrolled in the Joint Asia Diabetes Evaluation (JADE) Register. In a subsequent interview with Omnihealth Practice, Prof. Chan shared further insights on the application of the JADE® Program, shedding light on the dynamics between glycemic management strategies and patients’ HRQoL.